Log In
BCIQ
Print this Print this
 

seliciclib (R-roscovitine) (CYC202)

  Manage Alerts
Collapse Summary General Information
Company Cyclacel Pharmaceuticals Inc.
DescriptionFirst-generation inhibitor of cyclin dependent kinases 2E, 2A, 7 and 9
Molecular Target Cyclin dependent kinase (CDK)
Mechanism of ActionCyclin dependent kinase (CDK) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/29/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today